Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

IgA nephropathy has transitioned from a neglected rare disease to a high-priority drug development area, driven by academic innovation and FDA regulatory agility. Seven global drug approvals in five years highlight this shift, with next-generation therapies targeting APRIL, BAF, and CD38 to improve patient outcomes and dosing intervals. Beyond renal disease, the biopharma industry is navigating a complex landscape involving the FDA commissioner confirmation process for Heidi Overton, where vaccine safety and agency management remain critical focal points. Meanwhile, reverse mergers have emerged as a strategic, capital-efficient alternative to traditional IPOs, particularly when paired with private investments in public equity (PIPEs). These trends, alongside significant preclinical deals like Merck’s recent acquisition, reflect a broader push for innovation and financial stability within the evolving biopharmaceutical sector.